According to a report from UBS, pharma stocks listed in Mainland China and Hong Kong have snowballed by 27% and 65% respectively this year as driven by a series of record-breaking high-value licensing deals and clinical data releases in 1H25. The broker estimated that companies with licensing potential and upcoming clinical data announcements would still have upside potential.

UBS raised its target price for CSPC PHARMA (01093.HK)  -0.180 (-2.258%)    Short selling $62.58M; Ratio 9.636%   to HKD10 and reiterated a Buy rating, noting that the expected licensing deals and effective sales expense control haven't yet been reflected in the stock price.

Related NewsBOCOMI Ratings, TPs on Pharmas (Table)
The broker also lifted its target price for CARSGEN-B (02171.HK)  -0.950 (-4.025%)    Short selling $2.22M; Ratio 7.005%   to HKD32 and maintained a Buy rating, given its increasing market share in China and expected upside potential for overseas market expansion.

Company｜Rating｜Target Price (HKD)
CSPC PHARMA (01093.HK)  -0.180 (-2.258%)    Short selling $62.58M; Ratio 9.636%   ｜Buy｜10
HANSOH PHARMA (03692.HK)  -0.550 (-1.877%)    Short selling $10.92M; Ratio 10.458%   ｜Buy｜33.3
SINO BIOPHARM (01177.HK)  -0.110 (-2.099%)    Short selling $47.69M; Ratio 12.956%   ｜Buy｜5.6
SIMCERE PHARMA (02096.HK)  -0.080 (-0.726%)    Short selling $2.51M; Ratio 3.474%   ｜Buy｜10.4
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-26 12:25.)